UniSuper Management Pty Ltd Purchases 20,862 Shares of Moderna, Inc. (NASDAQ:MRNA)

UniSuper Management Pty Ltd lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 69.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,953 shares of the company’s stock after acquiring an additional 20,862 shares during the period. UniSuper Management Pty Ltd’s holdings in Moderna were worth $2,119,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. WINTON GROUP Ltd purchased a new position in shares of Moderna in the fourth quarter worth $770,000. Crowley Wealth Management Inc. purchased a new position in Moderna in the 4th quarter worth about $41,000. LPL Financial LLC lifted its stake in Moderna by 274.6% during the 4th quarter. LPL Financial LLC now owns 367,878 shares of the company’s stock valued at $15,296,000 after acquiring an additional 269,682 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Moderna during the 4th quarter valued at about $4,441,000. Finally, American Century Companies Inc. grew its stake in shares of Moderna by 2.7% in the fourth quarter. American Century Companies Inc. now owns 44,619 shares of the company’s stock worth $1,855,000 after acquiring an additional 1,187 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 3.1 %

NASDAQ MRNA opened at $31.12 on Monday. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The stock’s 50 day moving average is $34.72 and its 200 day moving average is $44.13. The stock has a market cap of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MRNA shares. Morgan Stanley dropped their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.